Mike Stedman

Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data

Adrian Heald, Mike Stedman, Mark Davies et al. · Cardiovascular Endocrinology & Metabolism · 2020 · 236 citations · Full text

Medicine, Chronic Disease Control, Internal Medicine +17

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 95 citations · Full text

Medicine, Endocrinology, Pharmacology +14

LIVING WITH COVID-19: BALANCING COSTS AGAINST BENEFITS IN THE FACE OF THE VIRUS

David Miles, Mike Stedman, Adrian Heald · National Institute Economic Review · 2020 · 83 citations

Public Affairs, Health Policy, Public Policy +9

Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation

Mike Stedman, Mark Lunt, Mark Davies et al. · BMJ Open · 2020 · 61 citations · Full text

Social Sciences, Health Care Management, Pharmacoeconomics +17

A phased approach to unlocking during the COVID‐19 pandemic—Lessons from trend analysis

Mike Stedman, Mark Davies, Mark Lunt et al. · International Journal of Clinical Practice · 2020 · 42 citations · Full text

Veterinary Medicine, Health Policy, Infectious Diseases +16